Tags : CIRRUS HD-OCT

Zeiss’ CIRRUS HD-OCT Receives FDA’s 510 (k) Clearance for Epithelial

Vartika Singh March 8, 2019

Shots: CIRRUS HD-OCT provides a mapping of epithelial thickness (up to 9mm), monitors cornea response in ophthalmic diseases including dry eye & keratoconus The FDA’s 510(k) clearance improves Zeiss’ footprints […]readmore

Tags : CIRRUS HD-OCT

Zeiss’ CIRRUS HD-OCT Receives FDA’s 510 (k) Clearance for Epithelial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CIRRUS HD-OCT

Zeiss’ CIRRUS HD-OCT Receives FDA’s 510 (k) Clearance for Epithelial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company